Modification of Vancomycin Dosing in Cardiac Surgery With Cardiopulmonary Bypass.
cardiac surgery
cardiopulmonary bypass
dosing regimen
surgical-site infections
vancomycin
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
26
08
2022
accepted:
23
11
2022
pubmed:
3
12
2022
medline:
15
3
2023
entrez:
2
12
2022
Statut:
ppublish
Résumé
This study aims to assess the risk factors for insufficient vancomycin concentrations for its prophylactic use in adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) and to modify the dosing regimen to achieve appropriate plasma concentrations. A total of 27 patients with vancomycin dosing of 1 to 1.5 g based on a weight cutoff of 67 kg were included, of which only 13 (48.15%) had vancomycin plasma concentration >15 mg/L at surgical closure. Risk factors of vancomycin concentration <15 mg/L at surgical-site closure were confirmed by multivariate logistic regression analysis, which showed that CPB duration was an independent predictor. Patients with CPB duration >4 hours had significantly lower vancomycin concentrations and lower proportion in achieving target vancomycin concentration at the end of CPB and surgical closure. For patients with CPB >4 hours, the modified dosing regimen that a second dose of 0.5 to 0.75 g added at 4 hours since the onset of CPB improved the target achievement of vancomycin concentration at surgical closure. Taken together, CPB duration >4 hours was the risk factor for insufficient vancomycin concentration at surgical closure, while our modified dosing could improve the vancomycin concentrations for its prophylactic use in patients undergoing cardiac surgery with CPB.
Substances chimiques
Vancomycin
6Q205EH1VU
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
490-497Informations de copyright
© 2022, The American College of Clinical Pharmacology.
Références
Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195-283.
Morisaki A, Hosono M, Sasaki Y, et al. Evaluation of risk factors for hospital mortality and current treatment for poststernotomy mediastinitis. Gen Thorac Cardiovasc Surg. 2011;59(4):261-267.
Goodman JS, Schaffner W, Collins HA, Battersby EJ, Koenig MG. Infection after cardiovascular surgery. Clinical study including examination of antimicrobial prophylaxis. N Engl J Med. 1968;278(3):117-123.
Kreter B, Woods M. Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trials. J Thorac Cardiovasc Surg. 1992;104(3):590-599.
Lador A, Nasir H, Mansur N, et al. Antibiotic prophylaxis in cardiac surgery: systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(3):541-550.
Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann Thorac Surg. 2007;83(4):1569-1576.
Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013;14(1):73-156.
Krivoy N, Yanovsky B, Kophit A, et al. Vancomycin sequestration during cardiopulmonary bypass surgery. J Infect. 2002;45(2):90-95.
Buylaert WA, Herregods LL, Mortier EP, Bogaert MG. Cardiopulmonary bypass and the pharmacokinetics of drugs. An update. Clin Pharmacokinet. 1989;17(1):10-26.
Fellinger EK, Leavitt BJ, Hebert JC. Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery. Ann Thorac Surg. 2002;74(4):1187-1190.
Klamerus KJ, Rodvold KA, Silverman NA, Levitsky S. Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition. Antimicrob Agents Chemother. 1988;32(5):631-635.
van der Starre PJ, Kolz M, Lemmens HJ, Faix JD, Mitchell S, Miller C. Vancomycin plasma concentrations in cardiac surgery with the use of profound hypothermic circulatory arrest. Eur J Cardiothorac Surg. 2010;38(6):741-744.
Miglioli PA, Merlo F, Grabocka E, Padrini R. Effects of cardio-pulmonary bypass on vancomycin plasma concentration decay. Pharmacol Res. 1998;38(4):275-278.
Paruk F, Sime FB, Lipman J, Roberts JA. Dosing antibiotic prophylaxis during cardiopulmonary bypass-a higher level of complexity? A structured review. Int J Antimicrob Agents. 2017;49(4):395-402.
Ortega GM, Martí-Bonmatí E, Guevara SJ, Gómez IG. Alteration of vancomycin pharmacokinetics during cardiopulmonary bypass in patients undergoing cardiac surgery. Am J Health Syst Pharm. 2003;60(3):260-265.
Cotogni P, Passera R, Barbero C, et al. Intraoperative vancomycin pharmacokinetics in cardiac surgery with or without cardiopulmonary bypass. Ann Pharmacother. 2013;47(4):455-463.
Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-e55.
Hafermann MJ, Kiser TH, Lyda C, et al. Weight-based versus set dosing of vancomycin for coronary artery bypass grafting or aortic valve surgery. J Thorac Cardiovasc Surg. 2014;147(6):1925-1930.
Garey KW, Dao T, Chen H, et al. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother. 2006;58(3):645-650.
Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev. 2010;31(1):21-24.
Albacker TB, Alqattan H, Alqahtani SA, et al. Serum level of prophylactic antibiotics in cardiac surgery and its implication on surgical site infection (SSI). Am J Cardiovasc Dis. 2022;12(4):233-239.
Sanders FRK, Goslings JC, Mathôt RAA, Schepers T. Target site antibiotic concentrations in orthopedic/trauma extremity surgery: is prophylactic cefazolin adequately dosed? A systematic review and meta-analysis. Acta Orthop. 2019;90(2):97-104.
Vallesi L, Fragasso T, Benegni S, et al. Vancomycin prophylaxis in paediatric patients following cardiac surgery: a retrospective evaluation of trough levels and associated variables. Interact Cardiovasc Thorac Surg. 2020;31(5):667-673.
Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82-98.
Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835-864.
Hatzopoulos FK, Stile-Calligaro IL, Rodvold KA, Sullivan-Bolyai J, Del Nido P, Levitsky S. Pharmacokinetics of intravenous vancomycin in pediatric cardiopulmonary bypass surgery. Pediatr Infect Dis J. 1993;12(4):300-304.
Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507-514.
Suzuki Y, Kawasaki K, Sato Y, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia. Chemotherapy. 2012;58(4):308-312.